Astra Industrial Group — Capital/Financing Update 2021

Jun 13, 2021

AIG announces that one of its subsidiaries Tabuk Pharmaceutical has signed a contract with Moderna to commercialize Moderna’s COVID-19 Vaccine and its variants in Saudi Arabia

1212 · 13/06/2021 08:02:01 · Announcement #63739 · View on Saudi Exchange

AIG announces that one of its subsidiaries Tabuk Pharmaceutical has signed a contract with Moderna to commercialize Moderna’s COVID-19 Vaccine and its variants in Saudi Arabia

Element List	Explanation
Introduction	AIG announces that one of its subsidiaries Tabuk Pharmaceutical has signed exclusive service agreement with Moderna Switzerland Gmbh to sell and distribute their mRNA COVID 19 vaccine including the variant products in Saudi Arabia.
Date of Announcement of the Award	2021-06-11 Corresponding to 1442-11-01
Contract Subject Matter	Exclusivity service agreement of Moderna’s mRNA COVID 19 Vaccine and its variants in KSA.
Date of Signing the Contract	2021-06-11 Corresponding to 1442-11-01
Contract Value	Difficult to determine since it is dependent on the level of supply and sales to the market which is dependent on successful registration of the products.
Contract Details	An exclusive service agreement was signed with Moderna Switzerland Gmbh a fully owned subsidiary of Moderna TX Inc an American company to sell and distribute their mRNA COVID 19 vaccines and its variants developed by Moderna for public and private sectors in KSA.

Tabuk will hold the Marketing Authorization for the product during the term of the Agreement.

In addition to the above, the agreement scope includes obtaining and maintaining any required authorization including registration of the products with SFDA and carrying out pharmacovigilance activities. It also includes providing suitable handling of the products for the distribution to wholesalers, hospitals, clinics and others.

The agreement also gives Tabuk the possibility to discuss expanded business opportunities involving Moderna in the Kingdom or outside the Kingdom for Moderna products other than the COVID 19 Vaccines and its variants if authorized in the future. Contract Duration 3 years renewable upon both parties consent. Financial Impact and the Relevant Period It difficult to assess the financial impact of this agreement since it is related to the level of supply and sales to the market which is dependent successful registration of the products. Any material financial impact will be announced in the upcoming interim and annual financial statements. Related Parties None

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.